Patents Examined by Erinne R Dabkowski
-
Patent number: 11965041Abstract: The present invention provides N-methylated cyclic hexapeptides comprising RGD and at least one alanine residue. The present invention further provides prodrugs comprising the cyclic hexapeptides. Pharmaceutical compositions comprising said cyclic hexapeptides are also disclosed as well as methods of their production and use in treating integrin related conditions and diseases.Type: GrantFiled: September 17, 2018Date of Patent: April 23, 2024Assignee: TECHNISCHE UNIVERSITAET MUENCHENInventors: Horst Otto Kessler, Chaim Gilon, Amnon Hoffman, Michael Weinmuller, Florian Rechenmacher, Joseph Fanous, Adi Klinger
-
Patent number: 11951150Abstract: The present invention relates to compositions and methods for preventing and reducing inflammation and preventing and treating diseases and disorders associated with inflammation. It has been shown that CRADD plays a pivotal role in maintaining the integrity of endothelial monolayers. The recombinant cell-penetrating CRADD protein (CP-CRADD)-based compositions and methods described herein provide for the development of a novel treatment for inflammatory vascular disorders including cardiovascular, cerebrovascular, respiratory, gastrointestinal, and renal systems.Type: GrantFiled: June 7, 2021Date of Patent: April 9, 2024Assignee: Vanderbilt UniversityInventors: Jack J. Hawiger, Ruth Ann Veach, Yan Liu, Huan Qiao, Lukasz S. Wylezinski
-
Patent number: 11952415Abstract: The invention relates to a polypeptide, such as an Affimer polypeptide, comprising an amino acid sequence having at least 80% identity to amino acid residues 1 to 11, 13 to 15, 17 to 19, 21 to 25, 27 to 28, 35 to 37, 39, 41, 43 to 44, 46 to 47, 49 to 50, 52 to 53, 55 to 58, 63 to 64, 66, 68 to 82, 84 to 85, and 87 to 98 of SEQ ID NO: 1; characterised in that said polypeptide comprises one or more mutations relative to SEQ ID NO: 1 selected from the group consisting of: T51L, T51V, M65V, N32G, A59I, L38A, V20I, A40I, L38V, A12I, A12V, I16L, V20L, Q26E, E29M, T31K, N32D, N32H, T34V, T34R, T34D, T34P, A40V, Q42D, T45I, T45V, V48E, V48G, V48A, T51F, T51A, A59L, L67I, (V20I, L38A), (V20L, L38A), (V20I, L38V), (V20L, L38V), (E29K, K30E, E33K), (Y54D, T83D, Q86E), (A59L, G60N, D61G, N62K), (A59V, D61N, N62K), (G60N, D61G, N62K), (G60N, ?D61, N62G), ?D61, (A59L, G60N, ?D61, N62G), (A59V, G60N, D61G, N62K), (A59I, G60N, D61G, N62K), (A59I, G60N, ?D61, N62G), (A59V, G60N, ?D61, N62G), (A59V, ?D61), (G60P, ?D61, N62P),Type: GrantFiled: July 2, 2018Date of Patent: April 9, 2024Assignee: Avacta Life Sciences LimitedInventors: Geoffrey William Platt, Graham Robert Pye-Smith Spence
-
Patent number: 11938198Abstract: The present invention provides a method of treating heart failure with reduced ejection fraction, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the anchoring of PP2A to mAKAP?. This composition is preferably in the form of a viral based gene therapy vector that encodes a fragment of mAKAP? to which PP2A binds.Type: GrantFiled: March 13, 2020Date of Patent: March 26, 2024Assignees: University of Miami, The Board of Trustees of the Leland Stanford Junior UniversityInventors: Michael S. Kapiloff, Jinliang Li
-
Patent number: 11939365Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated human p53. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: GrantFiled: September 17, 2018Date of Patent: March 26, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Drew C. Deniger, Steven A. Rosenberg, Anna Pasetto, Rami Yoseph, Winifred M. Lo, Yong-Chen Lu, Maria R. Parkhurst, Paul F. Robbins, Parisa Malekzadeh
-
Patent number: 11912752Abstract: A novel PTH(1-34) mimetic peptide based on protein domain reconstruction. The mimetic peptide contains peptide fragment repeats at 29th-34th positions. The amino acid at the 34th position and the last amino acid of the peptide fragment repeats at the 29th-34th positions are changed from phenylalanine (Phe, F) into tyrosine (Tyr, Y), so that MY-3 peptide is formed. Preclinical experiments show that the MY-3 mimetic peptide promotes osteoblast differentiation and has a very good effect in treating osteoporosis and promoting bone growth. The anti-osteoporosis effect of the MY-3 mimetic peptide is better than that of the PTH (1-34) (The product name on the market is Forsteo or Parathyroid), so that the MY-3 mimetic peptide has a significant clinical application prospect.Type: GrantFiled: April 29, 2021Date of Patent: February 27, 2024Inventor: Dehong Yang
-
Patent number: 11884706Abstract: The present invention relates to an immunomodulating peptide comprising an amino acid sequence as shown in SEQ ID NO:1. The present invention also discloses use of the immunomodulating peptide in the preparation of a drug or skin care product for promoting skin wound healing. The present invention provides a new immunomodulating peptide and use thereof, and discloses the mechanism of action of the immunomodulating peptide in promoting wound healing. The immunomodulating peptide is useful as a wounding healing polypeptide template.Type: GrantFiled: August 7, 2020Date of Patent: January 30, 2024Assignee: SOOCHOW UNIVERSITYInventors: Lin Wei, Yang Yang, Wei Xu
-
Patent number: 11872261Abstract: Described herein is the design and construction of a class of lipoprotein targeting protease inhibitors. Small peptides with protease inhibitor activity are conjugated to hydrophobic, lipoprotein targeting molecules using, for instance, amine reactive chemistry. Methods of use of the resultant lipoprotein targeting protease inhibitor (antiprotease) molecules are also described. Also described is the production and use of protease inhibitor enriched HDL particles, as well as A1AT-peptide-enriched HDL particles, and their use in various therapeutic contexts.Type: GrantFiled: February 16, 2022Date of Patent: January 16, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Alan T. Remaley, Scott M. Gordon
-
Patent number: 11872298Abstract: The present invention relates to the non-therapeutic cosmetic use of a mixture of arthrofactins as a moisturizer particularly for the skin, mucosa and particularly dry skin.Type: GrantFiled: December 22, 2017Date of Patent: January 16, 2024Assignee: L'OREALInventors: Luiz Santos, Lucie Tournier-Couturier, Nakako Shibagaki
-
Patent number: 11865162Abstract: Methods for treating uremic cardiomyopathy are provided and include the step of administering a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject in need thereof. The polypeptide anatagonist can further include a cell penetrating polypeptide. Methods of treating anemia, including anemia-associated with chronic kidney disease, are also provided.Type: GrantFiled: June 30, 2017Date of Patent: January 9, 2024Assignee: MARSHALL UNIVERSITY RESEARCH CORPORATIONInventors: Zijian Xie, Joseph I. Shapiro, Jiang Liu
-
Patent number: 11866515Abstract: Provided herein are hemiasterlin derivatives, conjugates thereof, compositions comprising the derivatives or conjugates thereof, methods of producing the derivatives and conjugates thereof, and methods of using the derivatives, conjugates, and compositions for the treatment of cell proliferation. The derivatives, conjugates, and compositions are useful in methods of treatment and prevention of cell proliferation and cancer, methods of detection of cell proliferation and cancer, and methods of diagnosis of cell proliferation and cancer. In an embodiment, the hemiasterlin derivatives are according to Formula 1000: or a pharmaceutically acceptable salt, solvate, or tautomer thereof, wherein Ar, L, W1, W4, W5, SG, and R are as described herein.Type: GrantFiled: November 2, 2020Date of Patent: January 9, 2024Assignee: SUTRO BIOPHARMA, INC.Inventors: Toni Kline, Qun Yin, Krishna Bajjuri
-
Patent number: 11845807Abstract: The invention relates to carrier complexes and methods for delivering molecules to cells. The carrier complexes comprises a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In another embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a molecule and an aromatic cationic peptide.Type: GrantFiled: November 8, 2021Date of Patent: December 19, 2023Assignee: Cornell Research Foundation, Inc.Inventors: Hazel H. Szeto, Kesheng Zhao, Hugh Robertson, Alex V. Birk
-
Patent number: 11834516Abstract: The present invention relates to a novel tumor-specific polypeptide and use thereof. In particular, the present invention relates to a tumor-specific polypeptide having high affinity for HLA-A0201 and having cytotoxic T lymphocyte inducing ability, and its use for diagnosing, preventing and treating diseases (especially cancer) associated with high expression of the TWISTNB gene or mutation(s) in the TWISTNB gene.Type: GrantFiled: September 30, 2021Date of Patent: December 5, 2023Assignee: GENOIMMUNE THERAPEUTICS CO., LTD.Inventors: Yong Hou, Shuntao Luo, Ting An, Xiumei Lin, Bo Li, Guanglei Li
-
Patent number: 11820836Abstract: Provided are a polypeptide and nucleic acid for encoding the polypeptide, a nucleic-acid construct, an expression vector, and a host cell containing the nucleic acid, an antigen-presenting cell presenting the polypeptide on the surface of the cell, and immune effector cell thereof, a pharmaceutical composition containing the polypeptide, a vaccine containing the nucleic acid, the nucleic acid construct, the expression vector, the host cell, the antigen-presenting cell, and the immune effector cell, and an antibody recognizing the polypeptide. Also provided is a therapeutic method using the polypeptide, the nucleic acid, the pharmaceutical composition, the vaccine, and the antibody. Also provided are a diagnosis method and diagnosis apparatus for detecting the described polypeptide. Also provided is an application of the polypeptide in preparing a vaccine, a tumor diagnosis kit, or a pharmaceutical composition, and an application of the polypeptide or the nucleic acid as a test target in tumor diagnosis.Type: GrantFiled: May 5, 2022Date of Patent: November 21, 2023Assignee: BGI SHENZHENInventors: Yunxia Tang, Bo Li, Yong Hou, Ying Huang, Cheng Cheng, Shuntao Luo
-
Patent number: 11820802Abstract: The present invention is within the field of protein engineering and purification. The invention relates to a target-binding polypeptide mutant of an IgG binding polypeptide, such as Protein A, Protein G, Protein L or Protein M, comprising a metal binding motif. More closely the invention relates to an Fc binding ligand comprising an engineered protein based on the Protein A derived Z domain, to which a calcium binding EF-loop has been introduced.Type: GrantFiled: September 5, 2017Date of Patent: November 21, 2023Assignee: Cytiva BioProcess R&D ABInventors: Sophia Hober, Sara Kanje, Johan Nilvebrant
-
Patent number: 11814412Abstract: De novo artificial protein based reporters that may be expressed in eukaryotic (e.g., mammalian) cells and methods of using the same are provided herein.Type: GrantFiled: June 29, 2021Date of Patent: November 14, 2023Assignee: The Trustees of the University of PennsylvaniaInventors: Goutham Kodali, Molly Marie Sheehan, Joshua Mancini, Bohdana Marie Discher, Michael Magaraci, Nathan M. Ennist, Brian Chow, Peter Leslie Dutton, Christopher Moser
-
Patent number: 11814414Abstract: The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.Type: GrantFiled: February 8, 2021Date of Patent: November 14, 2023Assignee: REALTA HOLDINGS, LLCInventors: Neel K. Krishna, Kenji Cunnion
-
Patent number: 11807693Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.Type: GrantFiled: January 28, 2021Date of Patent: November 7, 2023Assignee: AMGEN INC.Inventors: Jerry Ryan Holder, Gayathri Swaminath, Michael J. Frohn, Brian Alan Lanman, Anthony B. Reed, Leslie P. Miranda, John Gordon Allen, Alexander J. Pickrell, Aaron C. Siegmund, Lewis D. Pennington, Bryant Yang
-
Patent number: 11753450Abstract: The Sequence Listing associated with this application is provided in text form in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is SequenceListing.txt. The text file is 36.3 KB, and was created on Sep. 30, 2020.Type: GrantFiled: July 2, 2020Date of Patent: September 12, 2023Assignee: Bioprocessia Technologies LLCInventor: Yinong Zong
-
Patent number: 11738067Abstract: Provided is an incretin, or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof, for use in a method of reducing elevated intracranial pressure (ICP) in a subject. Methods of reducing elevated ICP in a subject may comprise administering an incretin, or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof to the subject. The elevated ICP may be associated with idiopathic intracranial hypertension (IIH), secondary pseudotumour cerebri, hydrocephalus, normal pressure hydrocephalus, raised intracranial pressure secondary to a brain tumour, meningitis, brain trauma, brain injury, and venous sinus thrombosis.Type: GrantFiled: October 8, 2020Date of Patent: August 29, 2023Assignee: INVEX THERAPEUTICS LTD.Inventor: Alex Sinclair